Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027

CAR-T Digest - August 2020

17 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027

Alphamab Oncology continues to expand its ADC pipeline, announcing that the first patient has been dosed in a Phase 1 trial of JSKN027, marking the clinical debut of a first-in-class PD-L1/VEGFR2 bispecific ADC
This milestone comes at a time when advanced solid tumors remain a growing global burden, with limited treatment options driving the need for therapies that can simultaneously tackle multiple tumor survival mechanisms
JSKN027 is designed precisely with this goal in mind, combining dual targeting of PD-L1 and VEGFR2 to address both immune evasion and tumor angiogenesis, leveraging a synergistic biology that underpins resistance in many cancers
Built using advanced glycan-specific conjugation technology, the ADC integrates a cleavable linker and a topoisomerase I inhibitor payload, enabling a powerful three-pronged approach: targeted cytotoxicity, anti-angiogenic effects, and immune checkpoint blockade
With the Phase 1 study now underway, the focus shifts to evaluating safety, pharmacokinetics, and early antitumor activity potentially paving the way for a new multi-mechanistic treatment strategy across a broad range of solid tumors